Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Identifying Key Metrics and Analyzing Data on Performance Gaps Enhance MLR Review Processes

Data-driven analysis of key performance metrics can uncover hidden inefficiencies in MLR (medical, legal, and regulatory) review workflows for life sciences companies. By identifying and closing performance gaps, organizations can convert their compliance review processes from bottlenecks into competitive advantages. EY's approach emphasizes systematic measurement and continuous improvement within promotional material review.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By Annalise Ludtke · Jessy HorrellMlr ReviewPromotional Material Review ProcessPromotional Review Data
Share
Identifying Key Metrics and Analyzing Data on Performance Gaps Enhance MLR Review Processes

Key takeaways

01

Tracking the right KPIs in MLR review processes reveals workflow inefficiencies that are otherwise invisible to compliance teams.

02

Analyzing performance gaps enables life sciences companies to streamline promotional material approvals and reduce cycle times.

03

A data-driven MLR review strategy can reframe compliance from a cost center into a source of competitive differentiation.

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Leveraging data to refine and enhance the promotional material review (MLR) process has become crucial in the ever-evolving landscape of life sciences. Organizations striving for efficiency and compliance need to understand how best to utilize available data to impact their workflow and overall success significantly.

Organizations striving for efficiency and compliance need to understand how best to utilize available data to impact their workflow and overall success significantly.

How can organizations use data to improve their MLR review processes? What specific metrics and insights should they focus on?

This episode of “Amend & Progress,” Vodori’s go-to podcast for all things promotional material features Jessy Horrell, VP of Customer Success at Vodori. She joins the host of the show, Annalise Ludtke to discuss the real-time analysis of promotional review data, uncovering insights and exploring how organizations can utilize this data to drive process improvements.

Key Points of Discussion

  • High-Level Metrics: Analyzing key performance indicators (KPIs) such as average job duration, feedback incorporation time, and review duration compared to industry benchmarks.
  • Workload Distribution: Understanding the distribution of tasks among reviewers and identifying potential bottlenecks or resource imbalances.
  • Performance Gaps: Identifying bottom performers and discussing strategies for supporting and improving their performance.

Jessy Horrell serves as the VP of Customer Success at Vodori, where she oversees customer onboarding and ongoing success with Vodori’s products. With a data-driven approach, Jessy helps clients understand and utilize their data to make informed decisions and enhance their MLR processes. Jessy holds a degree in Business Administration and has received numerous accolades for her contributions to customer success in the life sciences industry.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

AL
Annalise Ludtke
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

AL
Annalise Ludtke

Manager, Life Sciences Regulatory & Compliance at EY

Annalise Ludtke is a manager at EY specializing in life sciences regulatory and compliance. She focuses on optimizing medical, legal, and regulatory (MLR) review processes through data-driven methodologies. Her work helps pharmaceutical and biotech organizations transform compliance workflows into operational advantages.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512